103 related articles for article (PubMed ID: 34968866)
21. IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma.
Long KB; Tooker G; Tooker E; Luque SL; Lee JW; Pan X; Beatty GL
Mol Cancer Ther; 2017 Sep; 16(9):1898-1908. PubMed ID: 28611107
[TBL] [Abstract][Full Text] [Related]
22. Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion.
Jiang H; Liu X; Knolhoff BL; Hegde S; Lee KB; Jiang H; Fields RC; Pachter JA; Lim KH; DeNardo DG
Gut; 2020 Jan; 69(1):122-132. PubMed ID: 31076405
[TBL] [Abstract][Full Text] [Related]
23. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
24. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
26. Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress.
Jiang X; Ma Y; Wang T; Zhou H; Wang K; Shi W; Qin L; Guan J; Li L; Long B; Wang J; Guan X; Ye H; Yang J; Yu Z; Jiao Z
Gastroenterology; 2023 Jun; 164(7):1232-1247. PubMed ID: 36842710
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-Kras
Vilimas T; Wang AQ; Patnaik S; Hughes EA; Singleton MD; Knotts Z; Li D; Frankowski K; Schlomer JJ; Guerin TM; Springer S; Drennan C; Dextras C; Wang C; Gilbert D; Southall N; Ferrer M; Huang S; Kozlov S; Marugan J; Xu X; Rudloff U
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1067-1080. PubMed ID: 30306263
[TBL] [Abstract][Full Text] [Related]
28. Dinaciclib prolongs survival in the
Yang J; Hu S; Shangguan J; Eresen A; Li Y; Ma Q; Yaghmai V; Benson Iii AB; Zhang Z
Am J Transl Res; 2020; 12(3):1031-1043. PubMed ID: 32269732
[TBL] [Abstract][Full Text] [Related]
29. α-Mangostin-encapsulated PLGA nanoparticles inhibit pancreatic carcinogenesis by targeting cancer stem cells in human, and transgenic (Kras(G12D), and Kras(G12D)/tp53R270H) mice.
Verma RK; Yu W; Shrivastava A; Shankar S; Srivastava RK
Sci Rep; 2016 Sep; 6():32743. PubMed ID: 27624879
[TBL] [Abstract][Full Text] [Related]
30. Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic injury.
Fendrich V; Jendryschek F; Beeck S; Albers M; Lauth M; Esni F; Heeger K; Dengler J; Slater EP; Holler JPN; Baier A; Bartsch DK; Waldmann J
Oncogene; 2018 Apr; 37(14):1845-1856. PubMed ID: 29367759
[TBL] [Abstract][Full Text] [Related]
31. β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer.
Renz BW; Takahashi R; Tanaka T; Macchini M; Hayakawa Y; Dantes Z; Maurer HC; Chen X; Jiang Z; Westphalen CB; Ilmer M; Valenti G; Mohanta SK; Habenicht AJR; Middelhoff M; Chu T; Nagar K; Tailor Y; Casadei R; Di Marco M; Kleespies A; Friedman RA; Remotti H; Reichert M; Worthley DL; Neumann J; Werner J; Iuga AC; Olive KP; Wang TC
Cancer Cell; 2018 Jan; 33(1):75-90.e7. PubMed ID: 29249692
[TBL] [Abstract][Full Text] [Related]
32. Mouse-Derived Allografts: A Complementary Model to the KPC Mice on Researching Pancreatic Cancer In Vivo.
Li J; Qian W; Qin T; Xiao Y; Cheng L; Cao J; Chen X; Ma Q; Wu Z
Comput Struct Biotechnol J; 2019; 17():498-506. PubMed ID: 31011408
[TBL] [Abstract][Full Text] [Related]
33. Expression of neuropeptide Y and its receptors Y1 and Y2 in pancreatic intraepithelial neoplasia and invasive pancreatic cancer in a transgenic mouse model and human samples of pancreatic cancer.
Waldmann J; Fendrich V; Reichert M; Hecker A; Bartsch DK; Padberg W; Holler JPN
J Surg Res; 2018 Mar; 223():230-236. PubMed ID: 29433879
[TBL] [Abstract][Full Text] [Related]
34. Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.
Lee JW; Komar CA; Bengsch F; Graham K; Beatty GL
Curr Protoc Pharmacol; 2016 Jun; 73():14.39.1-14.39.20. PubMed ID: 27248578
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice.
Rao CV; Mohammed A; Janakiram NB; Li Q; Ritchie RL; Lightfoot S; Vibhudutta A; Steele VE
Neoplasia; 2012 Sep; 14(9):778-87. PubMed ID: 23019409
[TBL] [Abstract][Full Text] [Related]
36. Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice.
Mackenzie GG; Huang L; Alston N; Ouyang N; Vrankova K; Mattheolabakis G; Constantinides PP; Rigas B
PLoS One; 2013; 8(5):e61532. PubMed ID: 23650499
[TBL] [Abstract][Full Text] [Related]
37. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
38. Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer.
Liby KT; Royce DB; Risingsong R; Williams CR; Maitra A; Hruban RH; Sporn MB
Cancer Prev Res (Phila); 2010 Nov; 3(11):1427-34. PubMed ID: 20959520
[TBL] [Abstract][Full Text] [Related]
39. High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
Tsutaho A; Hashimoto A; Hashimoto S; Hata S; Kachi S; Hirano S; Sabe H
Cell Commun Signal; 2020 Jun; 18(1):101. PubMed ID: 32580737
[TBL] [Abstract][Full Text] [Related]
40. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
